Nintx
Nintx is a Brazilian biotech startup that uses proprietary GAIApath and xGIbiomics platforms to develop multi-target plant-based therapies modulating human biology via the gut microbiome. It serves pharmaceutical, food/nutrition, and nutraceutical markets through licensing, contract research, and consumer health products.
- Company typePrivate
- Founded2021
- HeadquartersSão Paulo, Brazil
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Nintx does
Nintx (Next Innovative Therapeutics) is a Brazilian biotech startup founded in 2021 that develops multi-target therapies leveraging the country's biodiversity and the human gut microbiome. The company's scientific premise is that most major diseases (cancer, neurodegenerative, cardiometabolic, immunological, and inflammatory bowel diseases) are multifactorial and linked to complex interactions between genetic, environmental, and microbiome factors, and that plant-based natural products can modulate human targets both directly and indirectly via interspecies molecular crosstalk with gut microorganisms.
Nintx operates two proprietary technology platforms: GAIApath, a data analytics knowledge graph used to map and select medicinal plants from Brazilian biodiversity capable of modulating targets and the gut microbiome concomitantly; and xGIbiomics, an in vitro platform that emulates the human gastrointestinal digestive system (controlling pH, volume, agitation, flow rate, temperature, enzymes, microorganisms, anaerobiosis, O2 levels, and metabolites) to study short- and long-term gut microbiome modulation. The pipeline includes seven pharmaceutical programs (NTX-03 cardiometabolic, NTX-04 IBS, NTX-05 immuno-oncology, NTX-06 IBD, NTX-10 Alzheimer's, NTX-11 metabolic syndrome, NTX-12 psoriasis) and ten nutraceutical products (PBTX-01 through PBTX-12) covering newborn GI health, gluten sensitivity, digestive support, gut-barrier restoration, gut-brain and gut-skin axis modulation, immune health, circadian rhythm, and mitochondrial metabolism.
The business model is B2B, combining three revenue streams: pharmaceutical licensing and co-development with major pharma (planned within five years), contract microbiome research services for food and nutrition companies (e.g., Lactalis), and nutraceutical product launches through partner laboratories. The company is pre-revenue, headquartered in São Paulo with an R&D lab in Campinas (the first private human intestinal microbiome laboratory in Latin America), and has raised approximately US$16 million across a US$3M seed (2022), a US$10M Series A (2024), and ~US$3M in grants from FINEP and PIPE/Fapesp.
Nintx firmographics
Firmographics- Name
- Nintx
- Legal name
- Nintx
- Website
- https://nintx.com.br
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Nintx is a Brazilian biotech startup that uses proprietary GAIApath and xGIbiomics platforms to develop multi-target plant-based therapies modulating human biology via the gut microbiome. It serves pharmaceutical, food/nutrition, and nutraceutical markets through licensing, contract research, and consumer health products.
- Ownership category
- akta.pro rank
Nintx industry classification
Industry- Product category
- Biotechnology Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling) (HLAAAFAK)
Keywords
Where Nintx is headquartered
LocationHeadquarters
- HQ city
- São Paulo
- HQ country
- Brazil
- HQ region
- Latin America
Offices2 records
Markets served
Nintx business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Pharmaceutical Licensing and Co-development: Plans to commercialize technology to major pharmaceutical companies within five years through licensing deals and co-development partnerships for drug programs targeting multifactorial diseases.
- Nutraceutical Product Development: Development and launch of nutraceutical products including formulas for gluten-intolerant patients, digestive support, microbiome modulation, and other health applications. First launch planned through partner laboratory.
- Contract Research Services: Provides gut microbiome research services to food and nutrition companies using proprietary xGIbiomics technology, such as the Lactalis collaboration for prebiotic ingredient validation.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
Nintx product offering
Product offeringCore offering
Nintx develops a new generation of medicines by leveraging Brazilian biodiversity and gut microbiome science. Its core consists of two proprietary platforms—GAIApath® (a knowledge graph for selecting medicinal plants) and xGIbiomics® (an in vitro gut microbiome simulator)—used to discover and develop multi-target pharmaceutical programs (NTX series) and nutraceutical products (PBTX series). The company offers contract gut microbiome research services to food and nutrition companies and plans to license and co-develop its drug pipeline with major pharmaceutical companies within five years.
Product overview
Nintx (Next Innovative Therapeutics) is a biotech company founded in Brazil in 2021 that develops multi-target therapies based on Brazilian biodiversity, focusing on plant-based natural products to modulate human biological targets directly and indirectly via the gut microbiome. The company's core offerings consist of two proprietary technology platforms: GAIApath® (data analytics knowledge graph for medicinal plant selection) and xGIbiomics® (in vitro gut microbiome simulation technology). Nintx's product portfolio includes a pharmaceutical pipeline with 7 drug programs (NTX-03, NTX-04, NTX-05, NTX-06, NTX-10, NTX-11, NTX-12) targeting cardiometabolic, gastroenterology, immunology, neuroscience, and dermatology conditions, and a nutraceutical pipeline with 10 products (PBTX-01 through PBTX-12) addressing gut health, microbiome modulation, immune support, and metabolic functions. The company operates in both pharmaceutical and nutraceutical markets, with plans to commercialize technology to major pharmaceutical companies within five years.
Differentiator
Problem solved
Functional benefit
Brands
- GAIApath®: Nintx's proprietary data analytics knowledge graph infrastructure to map and select medicinal plants from nature's biodiversity with the ability to modulate targets and the gut microbiome concomitantly.
- xGIbiomics®
Products and services
- xGIbiomics® Gut Microbiome Research Services Contract gut microbiome research services delivered using Nintx's proprietary xGIbiomics in vitro platform, which emulates the human gastrointestinal digestive system (pH, volume, agitation, flow rate, temperature, enzymes, microorganisms, anaerobiosis, O2 level, metabolites). Services are offered to food, dairy, and nutrition companies for prebiotic and synbiotic ingredient validation, functional food development, and gut health research.
- PBTX Nutraceutical Product Line A planned portfolio of 12 plant-based, microbiome-modulating nutraceutical products (PBTX-01 through PBTX-12) addressing newborn gastrointestinal health, non-celiac gluten sensitivity, broad-spectrum digestive support, irritable bowel syndrome, gut-barrier restoration, gut-brain axis modulation, gut-skin axis modulation, immune health, circadian cycle modulation, and mitochondrial metabolism. First product (PBTX-02) is being launched through a partner laboratory in Brazil.
- NTX Multi-Target Therapy Co-Development Programs Pre-clinical multi-target drug programs (NTX-03 cardiometabolic/liver-cardiac regeneration, NTX-04 IBS, NTX-05 immuno-oncology, NTX-06 inflammatory bowel disease, NTX-10 Alzheimer's, NTX-11 metabolic syndrome, NTX-12 psoriasis) developed for licensing and co-development with major pharmaceutical companies within five years. First program is the Centroflora-partnered Amazon-sourced multi-target therapy for an undisclosed therapeutic area.
Quantifiable outcome
- Lactose demonstrated as viable prebiotic alternative to inulin in synbiotic formulations, promoting enhanced production of short-chain fatty acids and growth of beneficial bacteria (Lactobacillus and Bifidobacterium)
- +1 more outcomes
Companies that use Nintx
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
Nintx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Nintx partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- CIEnP (Center for Innovation and Pre-Clinical Trials)corePartnership for pre-clinical development of multi-target therapy with global reach for inflammatory bowel disease based on Brazilian biodiversity. Project won FINEP Innovation Award 2025.
- Grupo CentrofloracoreCo-development partnership to create innovative multi-target therapy using Amazon rainforest herbaceous plant. Centroflora provides cultivation and extraction expertise; Nintx provides discovery and development capabilities.
- Embrapii (Brazilian Company of Industrial Research and Innovation)minorProvides support for the multi-target therapy project with expertise and resources for innovation.
- Grupo LactalisminorWorld's largest dairy company engaged Nintx for gut microbiome research using xGIbiomics technology to explore lactose as a prebiotic ingredient. Resulted in published scientific article.
- NaturaminorInvited Nintx CEO to participate in COP30 panel on 'Multiple Perspectives of Science and Technology in Favor of Amazonian Sociobiodiversity'. Partnership toward regenerative bioeconomy.
- ABIQUIFIminorBrazilian pharmaceutical association that organized Brazilian Pavillion, 4th Brazilian Startup Day, and BiodiversiTx session at BIO International Convention where Nintx conducted strategic meetings.
- Sindusfarma, RBIF, Biominas BrasilminorOrganizers of IV Brazilian Health Innovation Summit where CEO Stephani Saverio participated in panel on Intestinal Microbiota.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
Nintx competitors and assessment
Company assessmentDirect peers
- Vedanta Biosciences: Clinical-stage microbiome therapeutics company developing defined bacterial consortia for immune-mediated diseases. Directly comparable to Nintx as a microbiome-modulating drug discovery platform pursuing pharma partnerships and licensing economics.
- 4D pharma: UK-based microbiome therapeutics company developing single-strain live biotherapeutics for cancer, respiratory, and gastrointestinal indications. Comparable to Nintx in pursuing microbiome-based multi-target therapies and pharma licensing.
- Solarea Bio: US-based biotech harnessing interactions between plants and microorganisms to develop microbiome-modulating therapeutics. Closely aligned with Nintx's plant-microbiome interspecies approach and similar drug-discovery positioning.
- Second Genome: Microbiome drug discovery platform identifying microbiome-derived targets and therapeutics. Comparable to Nintx as a platform biotech leveraging microbiome science to develop novel drug candidates for partner pharma companies.
Broad incumbents
- Seres Therapeutics: Pioneer microbiome therapeutics company with SER-109 (VOWST) approved for recurrent C. difficile. Comparable as a leading microbiome-based drug developer targeting multifactorial indications via gut microbiome modulation.
- Eurofarma: Largest Brazilian-owned pharmaceutical company with diversified branded generics and innovation pipeline. Comparable as the most relevant Brazilian pharma incumbent that Nintx may seek as a domestic licensing or co-development partner.
- Aché Laboratórios: Major Brazilian pharmaceutical company with established branded generics, oncology, and innovation initiatives. Comparable regional incumbent that could serve as a Brazilian pharma licensing counterparty for Nintx's pipeline.
Emerging players
- BiomX: Clinical-stage microbiome company developing phage-based and engineered bacterial therapeutics. Comparable emerging player in the microbiome therapeutics category with similar small-cap, early-stage profile.
- Kaleido Biosciences: Previously public microbiome therapeutics company developing novel chemistries to modulate the gut microbiome. Comparable in therapeutic strategy and platform approach, though broader in indication scope.
Others
- Diversigen (Eurofins Genomics): Provider of microbiome sequencing, bioinformatics, and analytics services for pharma and academic clients. Comparable as an enabler/ecosystem participant whose services overlap with Nintx's xGIbiomics capabilities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Nintx social profiles
Digital presenceNintx financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nintx leadership team
Management profileNumber of profiles
Profiles10 records
Nintx funding detail
Funding detailFunding overview
Funding rounds3 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nintx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nintx
What does Nintx do?
Nintx develops a new generation of medicines by leveraging Brazilian biodiversity and gut microbiome science. Its core consists of two proprietary platforms—GAIApath® (a knowledge graph for selecting medicinal plants) and xGIbiomics® (an in vitro gut microbiome simulator)—used to discover and develop multi-target pharmaceutical programs (NTX series) and nutraceutical products (PBTX series). The company offers contract gut microbiome research services to food and nutrition companies and plans to license and co-develop its drug pipeline with major pharmaceutical companies within five years.
Is Nintx a public or private company?
Nintx is a private company. It is classified as venture growth investor backed and is currently operating.
When was Nintx founded?
Nintx was founded in 2021. It employs 1 to 10 people.
Where is Nintx based?
Nintx is headquartered in São Paulo, Brazil, in the Latin America region.
How does Nintx make money?
Three revenue lines are on record. Pharmaceutical Licensing and Co-development is the primary driver. The others are nutraceutical Product Development and contract Research Services.
Who are Nintx's main competitors?
Direct peers on record are Vedanta Biosciences, 4D pharma, Solarea Bio and Second Genome. Broad incumbents are Seres Therapeutics, Eurofarma and Aché Laboratórios. Emerging players are BiomX and Kaleido Biosciences. Diversigen (Eurofins Genomics) is listed as an others.
Does Nintx have an API?
No public API is recorded for Nintx.
What industry is Nintx in?
Nintx's product category is Biotechnology Drug Discovery. Its primary akta.pro industry code is HLAAAFAK, Microbiome Clinical Development & Translational Services (trial design, endpoints, sampling). Its NAICS code is 541714 and its SIC code is 2833.